Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism

Chest

Volumn 143, Issue 4, 2013, Pages 978-983

  Pimenta, Eduardo ^a,b   Stowasser, Michael ^a   Gordon, Richard D ^a   Harding, Susan M ^c   Batlouni, Michel ^b   Zhang, Bin ^e   Oparil, Suzanne ^d   Calhoun, David A ^c,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d University of Alabama at Birmingham   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; RENIN; SODIUM;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD PRESSURE MEASUREMENT; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HYPERALDOSTERONISM; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESISTANT HYPERTENSION; SALT INTAKE; SLEEP DISORDERED BREATHING; SODIUM RESTRICTION; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; URINALYSIS;

EID: 84875973070     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-0802     Document Type: Article

References (38)

1. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000; 342 (19): 1378 - 1384.
2. Grote L, Ploch T, Heitmann J, Knaack L, Penzel T, Peter JH. Sleep-related breathing disorder is an independent risk factor for systemic hypertension. Am J Respir Crit Care Med. 1999; 160 (6): 1875 - 1882.
3. Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA. 2000; 283 (14): 1829 - 1836.
4. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med. 2002; 165 (9): 1217 - 1239.
5. Somers VK, White DP, Amin R, et al American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology; American Heart Association Stroke Council; American Heart Association Council on Cardiovascular Nursing; American College of Cardiology Foundation. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation. 2008; 118 (10): 1080 - 1111.
6. Hirshkowitz M, Karacan I, Gurakar A, Williams RL. Hypertension, erectile dysfunction, and occult sleep apnea. Sleep. 1989; 12 (3): 223 - 232.
7. Kapa S, Sert Kuniyoshi FH, Somers VK. Sleep apnea and hypertension: interactions and implications for management. Hypertension. 2008; 51 (3): 605 - 608.
8. Worsnop CJ, Naughton MT, Barter CE, Morgan TO, Anderson AI, Pierce RJ. The prevalence of obstructive sleep apnea in hypertensives. Am J Respir Crit Care Med. 1998; 157 (1): 111 - 115.
9. Lavie P, Ben-Yosef R, Rubin AE. Prevalence of sleep apnea syndrome among patients with essential hypertension. Am Heart J. 1984; 108 (2): 373 - 376.
10. Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011; 58 (5): 811- 817.
11. Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001; 19 (12): 2271 - 2277.
12. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 2007; 131 (2): 453 - 459.
13. Calhoun DA, Harding SM. Sleep and hypertension. Chest. 2010; 138 (2): 434 - 443.
14. Tuomilehto J, Jousilahti P, Rastenyte D, et al. Urinary sodium excretion and cardiovascular mortality in Finland: a prospective study. Lancet. 2001; 357 (9259): 848 - 851.
15. Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ. 1988; 297 (6644): 319 - 328.
16. Sacks FM, Svetkey LP, Vollmer WM, et al DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001; 344 (1): 3 - 10.
17. Tunstall-Pedoe H, Woodward M, Tavendale R, A'Brook R, McCluskey MK. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: cohort study. BMJ. 1997; 315 (7110): 722 - 729.
18. Bibbins-Domingo K, Chertow GM, Coxson PG, et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med. 2010; 362 (7): 590 - 599.
19. Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009; 54 (3): 475 - 481.
20. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992; 120(6): 893 - 901.
21. Sato A, Saruta T. Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res. 2004; 27 (5): 303 - 310.
22. Pimenta E, Gaddam KK, Pratt-Ubunama MN, et al. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension. 2008; 51 (2): 339 - 344.
23. Pimenta E, Gordon RD, Ahmed AH, et al. Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study. J Clin Endocrinol Metab. 2011; 96 (9): 2813 - 2820.
24. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008; 51 (6): 1403 - 1419.
25. Chobanian AV, Bakris GL, Black HR, et al Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42 (6): 1206 - 1252.
26. Rechtschaffen A, Kales A. Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Sleep. Los Angeles, CA : Brain Information Service/Brain Research Institute, UCLA; 1968.
27. Funder JW, Carey RM, Fardella C, et al Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008; 93 (9): 3266 - 3281.
28. Pimenta E, Calhoun DA, Oparil S. Sleep apnea, aldosterone, and resistant hypertension. Prog Cardiovasc Dis. 2009; 51(5): 371 - 380.
29. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension. 2004; 43 (3): 518 - 524.
30. Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldos terone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest. 2004; 125 (1): 112 - 117.
31. Svatikova A, Olson LJ, Wolk R, et al. Obstructive sleep apnea and aldosterone. Sleep. 2009; 32 (12): 1589 - 1592.
32. Schwab RJ, Pasirstein M, Pierson R, et al. Identification of upper airway anatomic risk factors for obstructive sleep apnea with volumetric magnetic resonance imaging. Am J Respir Crit Care Med. 2003; 168 (5): 522 - 530.
33. Friedman O, Bradley TD, Chan CT, Parkes R, Logan AG. Relationship between overnight rostral fluid shift and obstructive sleep apnea in drug-resistant hypertension. Hypertension. 2010; 56 (6): 1077 - 1082.
34. Kasai T, Arcand J, Allard JP, et al. Relationship between sodium intake and sleep apnea in patients with heart failure. J Am Coll Cardiol. 2011; 58 (19): 1970 - 1974.
35. Gaddam K, Pimenta E, Thomas SJ, et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010; 24 (8): 532 - 537.
36. Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab. 2009; 94 (10): 3623 - 3630.
37. Nishizaka MK, Pratt-Ubunama M, Zaman MA, Cofield S, Calhoun DA. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens. 2005; 18 (6): 805 - 812.
38. Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension. 2002; 40 (6): 897 - 902.